Trials
Search / Trial NCT06417138

Comparative Effectiveness of Different Drugs Used to tr€at Patients in Rheumatoid Arthritis Saudi Database (RASD)"

Launched by UMM AL-QURA UNIVERSITY · May 13, 2024

Apply for Trial

Trial Information

Current as of March 13, 2025

Recruiting

Keywords

Rheumatoid Arthritis Remission Biological Dmar Ds Targeted Synthetic Dmar Ds Das 28 Crp Cdai Low Disease Activity Comparative Effectiveness Efficacy

ClinConnect Summary

This clinical trial is studying how effective different medications are for treating rheumatoid arthritis (RA) in patients in Saudi Arabia. Specifically, it compares biological drugs (bDMARDs) and targeted synthetic drugs (tsDMARDs) to find out which ones work best. Researchers will look at how well these medications reduce disease activity using two scoring systems: the Disease Activity Score - 28 joints - C-Reactive Protein (DAS-28-CRP) and the Clinical Disease Activity Index (CDAI). By analyzing the treatment data from patients in the Rheumatoid Arthritis Saudi Database (RASD), the aim is to determine the most effective drug for managing RA.

To participate in this study, individuals must be at least 18 years old, have a diagnosis of rheumatoid arthritis according to specific criteria, and have been under treatment for at least 12 months with a minimum of three visits to a healthcare provider during that time. Participants will need to give their consent to be included in the study, and they can expect their treatment information to be used to help researchers understand how different drugs perform in real-life settings. This trial is currently recruiting participants and welcomes both men and women.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • All those patients who are age of 18 years and above and
  • • meeting 2010 American College of Rheumatology classification criteria for rheumatoid arthritis.
  • • Both male and female gender will be included.
  • • There should be minimum of 12 months follow up with at least 3 documented visits of these patients to health care facilities.
  • Exclusion Criteria:
  • • Any patient who did not meet the inclusion criteria will be excluded from the study.
  • • Any patient who cannot recall the exact date of starting his drugs will be excluded during data analysis.

Trial Officials

Hani Almoallim, Professor

Principal Investigator

Umm Al-Qura University

About Umm Al Qura University

Umm Al-Qura University, located in Mecca, Saudi Arabia, is a prestigious institution dedicated to advancing education and research across various disciplines, including health sciences. As a clinical trial sponsor, the university is committed to fostering innovative research initiatives that contribute to the understanding and treatment of medical conditions. By leveraging its academic resources and expertise, Umm Al-Qura University aims to enhance clinical practices and improve patient outcomes through rigorous scientific investigation and collaboration with healthcare professionals and institutions.

Locations

Jeddah, Makkah, Saudi Arabia

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0